These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 3734266)
1. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. Rahko PS; Salerni R; Uretsky BF J Am Coll Cardiol; 1986 Aug; 8(2):436-40. PubMed ID: 3734266 [TBL] [Abstract][Full Text] [Related]
2. Left ventricular failure precipitated by chronic megaloblastic anemia. Hager WD; Callahan SK; deVlaming W Heart Lung; 1980; 9(2):299-302. PubMed ID: 6898609 [No Abstract] [Full Text] [Related]
3. [Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy]. Martín M; Estornell J; Orero M; Pérez JL; Ridocci F; Martínez V Rev Esp Cardiol; 2006 Jan; 59(1):75-7. PubMed ID: 16434009 [TBL] [Abstract][Full Text] [Related]
4. Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report. Cooray SD; Heerasing NM; Selkrig LA; Subramaniam VN; Hamblin PS; McDonald CJ; McLean CA; McNamara E; Leet AS; Roberts SK J Med Case Rep; 2018 Jan; 12(1):18. PubMed ID: 29373985 [TBL] [Abstract][Full Text] [Related]
5. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843 [TBL] [Abstract][Full Text] [Related]
6. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647 [TBL] [Abstract][Full Text] [Related]
7. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979 [TBL] [Abstract][Full Text] [Related]
8. [The disturbed elderly; a sometimes reversible process]. Abraham-Inpijn L Ned Tijdschr Tandheelkd; 1981 May; 88(5):178-80. PubMed ID: 6943434 [No Abstract] [Full Text] [Related]
9. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Wu KH; Chang JS; Tsai CH; Peng CT Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011 [TBL] [Abstract][Full Text] [Related]
10. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. Yang T; Brittenham GM; Dong WQ; Levy MN; Obejero-Paz CA; Kuryshev YA; Brown AM J Lab Clin Med; 2003 Nov; 142(5):332-40. PubMed ID: 14647037 [TBL] [Abstract][Full Text] [Related]
11. Nutritional anaemia in cirrhosis of the liver. Areekul S; Piankijagum A; Pravatmuang P; Cheeramakara C; Churdchu K Southeast Asian J Trop Med Public Health; 1981 Dec; 12(4):561-7. PubMed ID: 7344106 [No Abstract] [Full Text] [Related]
12. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174 [TBL] [Abstract][Full Text] [Related]
13. Iron chelation therapy in the management of transfusion-related cardiac iron overload. Fernandes JL Transfusion; 2012 Oct; 52(10):2256-68. PubMed ID: 22404719 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden. Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310 [TBL] [Abstract][Full Text] [Related]
15. [Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent]. Baudouy P; Lombrail P; Azancot I; Piekarski A; Martin E; Slama R Arch Mal Coeur Vaiss; 1983 Oct; 76(10):1240-6. PubMed ID: 6418103 [TBL] [Abstract][Full Text] [Related]
16. Fever in megaloblastic anemia. McKee LC South Med J; 1979 Nov; 72(11):1423-4, 1428. PubMed ID: 505076 [TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909 [TBL] [Abstract][Full Text] [Related]
18. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307 [TBL] [Abstract][Full Text] [Related]
19. [Reversible visual field defects and severe anemia]. Vangsted SP; Ring K Ugeskr Laeger; 1985 May; 147(21):1697-8. PubMed ID: 4024313 [No Abstract] [Full Text] [Related]